Cdc25C phosphatase (211-221)

inhibits G2 checkpoint

Also Known As:

CBP 501; CBP-501; CBP501

Networked: 10 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Cell Cycle Proteins: 807
    - cdc25 Phosphatases: 109
      - Cdc25C phosphatase (211-221): 10
  - Intracellular Signaling Peptides and Proteins: 32
    - Protein Tyrosine Phosphatases: 1685
      - Dual-Specificity Phosphatases: 295
        cdc25 Phosphatases: 109
        Cdc25C phosphatase (211-221): 10
    - Phosphoprotein Phosphatases: 1211
      - Dual-Specificity Phosphatases: 295
        cdc25 Phosphatases: 109
        Cdc25C phosphatase (211-221): 10
- Peptides: 82426
  - Peptide Fragments: 373
    - Cdc25C phosphatase (211-221): 10
Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Esterases: 1574
      - Phosphoric Monoester Hydrolases: 7477
        Protein Tyrosine Phosphatases: 1685
        Dual-Specificity Phosphatases: 295
        cdc25 Phosphatases: 109
        Cdc25C phosphatase (211-221): 10
        Phosphoprotein Phosphatases: 1211
        Dual-Specificity Phosphatases: 295
        cdc25 Phosphatases: 109
        Cdc25C phosphatase (211-221): 10
  - Multifunctional Enzymes: 108
    - Dual-Specificity Phosphatases: 295
      - cdc25 Phosphatases: 109
        Cdc25C phosphatase (211-221): 10

Experts

1.	Kawabe, Takumi: 7 articles (10/2017 - 01/2007)
2.	Kufe, Donald W: 7 articles (10/2017 - 01/2007)
3.	Mine, Naoki: 4 articles (09/2017 - 10/2011)
4.	Yamamoto, Sayaka: 4 articles (09/2017 - 01/2007)
5.	Sato, Takuji: 3 articles (10/2017 - 01/2007)
6.	Saito, Naoya: 3 articles (09/2017 - 10/2011)
7.	Von Hoff, Daniel D: 3 articles (09/2017 - 10/2011)
8.	Sakakibara, Keiichi: 2 articles (10/2017 - 09/2017)
9.	VonHoff, Daniel D: 2 articles (10/2017 - 09/2017)
10.	Ishigaki, Machiyo: 2 articles (10/2011 - 01/2007)

Related Diseases

1.	Neoplasms (Cancer) 10/03/2017 - "Furthermore, cotreatment of CDDP plus CBP501 significantly reduced the tumor growth and upregulated the percentage of tumor infiltrating CD8+ T cell in vivo. " 09/08/2017 - "Here, we investigated new aspects of the potential anti-tumor mechanism of action of CBP501 by examining its effects on the macrophages. " 01/01/2007 - "CBP501 is >100-fold more potent than TAT-S216A and retains its selectivity for cancer cells. " 09/08/2017 - "Taken together, these results offer potential new, unanticipated advantages of CBP501 treatment in anti-tumor therapy through a mechanism that entails the suppression of interactions between macrophages and cancer cells with suppression of sequential CSC-like cell formation in the tumor microenvironment." 05/15/2011 - "Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors."
2.	Malignant Mesothelioma 09/01/2014 - "CBP501 is an anticancer drug candidate that was investigated in two randomized phase II clinical trials for patients with nonsquamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). " 10/01/2011 - "CBP501 is an anticancer drug currently in randomized phase II clinical trials for patients with non-small cell lung cancer and malignant pleural mesothelioma. " 09/01/2014 - "Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/01/2014 - "CBP501 is an anticancer drug candidate that was investigated in two randomized phase II clinical trials for patients with nonsquamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). " 10/01/2011 - "CBP501 is an anticancer drug currently in randomized phase II clinical trials for patients with non-small cell lung cancer and malignant pleural mesothelioma. " 09/26/2017 - "Here we found that CBP501 inhibits migration of non-small cell lung cancer (NSCLC) cells in vitro, even in the presence of migration inducing factors such as WNT, IL-6, and several growth factors. " 09/26/2017 - "CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding."
4.	Mesothelioma 09/01/2014 - "Activity of CBP501 plus cisplatin was observed in patients with ovarian cancer and mesothelioma, including some patients previously treated with cisplatin. " 05/15/2011 - "Promising activity was observed with CBP501/cisplatin, mainly in ovarian and mesothelioma patients who had previously progressed on platinum-containing regimens. "
5.	Urticaria (Hives) 09/01/2014 - "In phase I clinical trials of CBP501 alone or in combination with cisplatin, the most common toxicity was infusion-related urticaria. "

Related Drugs and Biologics

1.	Platinum
2.	Immune Checkpoint Inhibitors
3.	Cisplatin (Platino)
4.	Pemetrexed (MTA)
5.	Calmodulin (Calcium-Dependent Activator Protein)
6.	DNA (Deoxyribonucleic Acid)
7.	Sodium
8.	Quercetin
9.	Proteins (Proteins, Gene)
10.	Doxorubicin (Adriamycin)

Related Therapies and Procedures

1.	Stents
2.	Therapeutics